Ads
related to: docetaxel and carboplatin breast cancer triple negative prognosis mayo clinic- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Nurses Station
Explore Resources Made For Nurses
To Learn About A mTNBC Treatment.
- Resources
Access Tools & Resources Available
To Help You Learn About A Treatment
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP
Breast cancer is the most common cancer in women worldwide, and can, rarely, also occur in men. There are many different types of breast cancer, of which triple-negative breast cancer is one of ...
Triple-negative is sometimes used as a surrogate term for basal-like. [2] Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers.
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]
The trial, known as CAPItello-290, was testing whether the drug combination improved overall survival in patients with inoperable or metastatic triple-negative breast cancer versus the older and ...
Ads
related to: docetaxel and carboplatin breast cancer triple negative prognosis mayo clinic